Platelet activation and coagulation cascade proteins

Platelet activation and coagulation cascade proteins represent a collective group of molecules essential for hemostasis, the process that stops bleeding at the site of vascular injury (StatPearls: Physiology, Hemostasis, 2023). This system is divided into primary hemostasis, involving platelet adhesion and aggregation, and secondary hemostasis, characterized by a proteolytic cascade of clotting factors that generates a fibrin mesh (NIH: The Blood Coagulation Cascade, 2010). Key proteins in this network include cell-surface receptors like P2Y12 and Glycoprotein IIb/IIIa on platelets, as well as enzymatic clotting factors such as Thrombin (Factor IIa) and Factor Xa (Nature Reviews Disease Primers: Platelets, 2017). Pathological overactivation of these proteins leads to thrombosis, causing conditions like myocardial infarction and stroke, while deficiencies result in bleeding disorders like hemophilia (PubMed: Thrombosis and Hemostasis, 2021). Because of their central role in cardiovascular health, these proteins are the primary targets for a wide range of antiplatelet and anticoagulant therapies designed to modulate clot formation and stability (PubChem: Anticoagulants, 2024).

Other names

Hemostatic proteinsBlood clotting factorsPlatelet activation pathway componentsCoagulation system proteins

Drugs targeting these proteins act by inhibiting specific steps in the hemostatic process, such as blocking platelet ADP receptors (P2Y12), inhibiting cyclooxygenase-1 (COX-1) to prevent thromboxane A2 synthesis, directly inhibiting Factor Xa or Thrombin, or interfering with the synthesis of vitamin K-dependent clotting factors (StatPearls: Anticoagulants, 2023; Nature Reviews: Antiplatelet Therapy, 2017).